Omnic Ocas

Phase 3Small molecule

BBerlin-Chemie AG Menarini Group

Omnic Ocas is one of 30 small molecule programs targeting Benign Prostatic Hyperplasia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Benign Prostatic HyperplasiaActive, not recruiting

Benign Prostatic HyperplasiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

110 competitors in Benign Prostatic Hyperplasia

#DrugCompanyPhaseTrials

Levitra

Bayer

Phase 3

1 2

Gemtesa

Sumitomo Pharma America, Inc.

Phase 3

2 3

Tamsulosin OCAS

Astellas

Phase 3

5 4

Botox

AbbVie

Phase 3

2 5

Evista

Eli Lilly

Phase 2

1 6

Drug Therapy

MMassachusetts General Hospital

Phase 3

1 7

Botox

RRevance Therapeutics, Inc.

Phase 2

3 8

Firmagon

Ferring

Phase 2

2 9

Zesly

MMezzion Pharma Co. Ltd

Phase 2

1 10

Viagra

VViatris Specialty LLC

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Benign Prostatic Hyperplasia1 trial

Efficacy and Safety of Tanzânia Association in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia

Completed·EEMS·Phase 3·NCT04185441·295 enrolled

Prolonged1 trial

A Comparative Bioavalability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tabsulosine 0.4 mg Tablets in Healthy Adult Male Subjects, at Steady State

Active, not recruiting·BBerlin-Chemie AG Menarini Group·Phase 1·NCT07146711·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Omnic Ocas. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Omnic Ocas compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Omnic Ocas. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Berlin-Chemie AG Menarini Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBerlin-Chemie AG Menarini Group

Omnic Ocas

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Benign Prostatic Hyperplasia1 trial

Prolonged1 trial

References

Drug Info

Quick Facts

Related News